BSX

As of 2026-09-10, BSX scores 43out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. BSX trades at $43.10, 3% below the band floor.

BSX scores 43 out of 100 on QNTM's five-factor model — a low-conviction reading — at 43 the factor profile is among the weaker names in the universe. Its strongest factor is value at 75 (strong), where it screens cheap on the model's valuation inputs, followed by sentiment at 54. The weakest is momentum at 15, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 36% of Healthcare names by composite.

On valuation, BSX is priced near the floor of its own recent range — the cheap end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 44. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on BSX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where BSX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for BSX runs $44.45–$67.77. Current price $43.10 sits 3% below the band floor. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.